Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sudden Reduction in Caffeine Intake Increases Serum Lithium Concentration to Supratherapeutic Level: A Case Report.

The primary care companion for CNS disorders·2024
Same author

Cardiovascular Safety of Amphetamine/Dextroamphetamine versus Methylphenidate in Older Adults.

Journal of pharmacy practice·2024
Same author

A Review of Therapeutics for Treatment-Resistant Depression in the Older Adult.

Drugs & aging·2023
Same author

History of Suicide Attempt and Clozapine Treatment in Veterans With Schizophrenia or Schizoaffective Disorder.

The primary care companion for CNS disorders·2022
Same author

Impact of Lithium on Suicidality in the Veteran Population.

Federal practitioner : for the health care professionals of the VA, DoD, and PHS·2022
Same author

An Evaluation of Nonacademic Predictors of Success in a Doctor of Pharmacy Program.

American journal of pharmaceutical education·2022
Same journal

Aripiprazole and Unexpected Salivation: A Case of Drug-Induced Sialorrhea Refractory to Anticholinergics.

Journal of pharmacy practice·2026
Same journal

Exploring Strategies to Educate Reproductive-Aged Individuals About Pharmacist-Prescribed Hormonal Contraception in Indiana: A Qualitative Study.

Journal of pharmacy practice·2026
Same journal

Assessing Kansas Pharmacy Preceptors' Experiences, Knowledge, and Attitudes Toward Pharmacogenomics.

Journal of pharmacy practice·2026
Same journal

The Impact of Academic Detailing on Clinician and Patient Outcomes: A Narrative Review.

Journal of pharmacy practice·2026
Same journal

Management of a Kratom and Tianeptine Overdose.

Journal of pharmacy practice·2026
Same journal

Strategies for Substituting ADHD Medications During Stimulant Shortages.

Journal of pharmacy practice·2026
See all related articles

Related Experiment Video

Updated: May 27, 2026

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

Targeting treatment-resistant depression.

Monica Mathys1, Brian G Mitchell

  • 1Texas Tech University Health Sciences Center School of Pharmacy, Dallas, TX 75216, USA. monica.mathys@ttuhsc.edu

Journal of Pharmacy Practice
|November 19, 2011
PubMed
Summary
This summary is machine-generated.

Many patients with depression do not respond to initial antidepressant treatments, becoming treatment-resistant. This review examines effective strategies for managing treatment-resistant depression (TRD) when standard therapies fail.

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
13:18

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

Related Experiment Videos

Last Updated: May 27, 2026

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
13:18

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

Area of Science:

  • Psychiatry
  • Clinical Psychology

Background:

  • Depression affects millions globally, with 50% of patients not achieving remission after two antidepressant trials, classifying them as treatment-resistant.
  • Treatment-resistant depression (TRD) is associated with significant functional impairment, physical health decline, suicidal ideation, and increased healthcare costs.
  • The efficacy of subsequent antidepressant trials diminishes with each failure, highlighting the need for alternative therapeutic strategies.

Purpose of the Study:

  • To conduct an evidence-based review of various antidepressant strategies for treatment-resistant depression.
  • To assess the efficacy and safety of different treatment options for patients who have not responded to initial antidepressant therapies.
  • To provide clinicians with guidance on selecting appropriate treatments for specific patients with TRD.

Main Methods:

  • Systematic literature search for evidence-based antidepressant strategies.
  • Review of studies assessing efficacy and safety profiles of different treatment modalities.
  • Analysis of clinical trial data and meta-analyses on treatment-resistant depression.

Main Results:

  • Evidence supports the efficacy of augmentation, combination, and switching strategies in TRD.
  • Specific pharmacologic agents and non-pharmacologic interventions show promise for non-responders.
  • Safety profiles vary across different treatment approaches, requiring careful patient selection.

Conclusions:

  • Effective management of TRD requires a tailored, evidence-based approach.
  • Clinicians can utilize reviewed strategies to optimize treatment outcomes for non-remitted patients.
  • Further research is needed to refine treatment algorithms and identify novel therapeutic targets for TRD.